{
    "Trade/Device Name(s)": [
        "VITEK 2 AST-Streptococcus Cefotaxime (\u22640.125 - \u22658 \u03bcg/mL)",
        "VITEK 2 AST-ST Cefotaxime (\u22640.125 - \u22658 \u03bcg/mL)"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K210287",
    "Predicate Device Reference 510(k) Number(s)": [
        "K121863"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON",
        "LTW",
        "LTT"
    ],
    "Summary Letter Date": "January 29, 2021",
    "Summary Letter Received Date": "February 2, 2021",
    "Submission Date": "January 29, 2021",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Cefotaxime"
    ],
    "Specimen Type(s)": [
        "Isolated colonies of Streptococcus spp."
    ],
    "Specimen Container(s)": [
        "Saline suspension (0.45-0.5% saline)"
    ],
    "Instrument(s)/Platform(s)": [
        "VITEK 2",
        "VITEK 2 Compact"
    ],
    "Method(s)/Technology(ies)": [
        "Automated quantitative antimicrobial susceptibility test",
        "Microdilution minimum inhibitory concentration (MIC) technique"
    ],
    "Methodologies": [
        "Automated MIC determination"
    ],
    "Submission Type(s)": [
        "Test",
        "Card",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for VITEK 2 AST-Streptococcus Cefotaxime antimicrobial susceptibility test card for Streptococcus spp. using VITEK 2 platforms",
    "Indications for Use Summary": "Designed for antimicrobial susceptibility testing of Streptococcus spp. with VITEK 2 and VITEK 2 Compact Systems as a laboratory aid in determining in vitro susceptibility to antimicrobial agents (Cefotaxime) for S. pneumoniae, beta-hemolytic Streptococcus, and Viridans Streptococcus.",
    "fda_folder": "Microbiology"
}